According to the market analysis report titled ‘Europe Breast Cancer Therapeutics Market Forecast 2028 By Therapy, Research Report, Country Outlook, COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share’, available with MarketStudyReport, Europe breast cancer therapeutics market is slated to record robust growth and reach a valuation of USD 12.9 billion by 2028.

As per report findings, factors such as the growing prevalence of breast cancer, penetration of several diagnostic & screening programs, advancements in breast cancer drugs, and mounting investments in research & development are driving Europe breast cancer therapeutics market growth.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4966050/   

Statistics available with the World Health Organization (WHO) claim that breast cancer is the fifth leading cause of cancer-related fatalities every year, and by 2020, nearly 7.8 billion women had got affected by the malignancy over the past five years.

Notably, clinical trials and drug development for treating breast cancer have found a new fervor in recent times due to increased focus on the disease management.

For instance, the United States Food and Drug Administration (FDA) authorized a new drug named Abemaciclib in October 2021, for patients suffering from HER2 and HR+ breast cancer malignances.

Similarly, two Phase 3 clinical trials are currently underway to test the efficiency of PARP inhibitors in conventional chemotherapy. In addition, Talazoparib is under observation within the OlympiAD and EMBRACA trials which is likely to amplify the expansion of Europe breast cancer therapeutics industry.

Both the trials disclose that patients with metastatic breast cancer and hereditary BRCA gene mutations showcased remarkable scope for recovery with the aid of the aforementioned drug with further evidence stating, patients that consume oral medication are likely to lead a better quality of life as compared to those who were not administered with such medications.

Based on therapy, the targeted therapy segment accounted for nearly 70% of Europe breast cancer therapeutics market share in 2021 and is estimated to grow substantially during the speculated timeline, owing to rigorous investments on R&D that fuel innovative treatment strategies.

From a regional frame of reference, Germany is likely to provide a boost to European breast cancer therapeutics market and reach a valuation of USD 2.2 billion by 2028, as the country has introduced a breast cancer screening program, which offers a free mammography every two years for women between the age group of 50-69 years to minimize the rising number of cases.

The competitive terrain of Europe breast cancer therapeutics marketplace is majorly influenced by key players such as Eisai Co. Ltd., Pfizer Inc., Sanofi S.A., Merck & Co. Inc., F. Hoffmann-La Roche AG, Amgen Inc., Novartis International AG, Bristol Myers Squibb, Eli Lilly and Company, and AstraZeneca plc.